Evidence
Nutrients. 2023 Mar 31;15(7):1729. doi: 10.3390/nu15071729.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease mainly characterized by the hepatic accumulation of lipid inducing a deregulation of β-oxidation. Its advanced form is non-alcoholic steatohepatitis (NASH), which, in addition to lipid accumulation, induces hepatocellular damage, oxidative stress and fibrosis that can progress to cirrhosis and to its final stage: hepatocellular carcinoma (HCC). To date, no specific therapeutic treatment exists. The implications of organ crosstalk have been highlighted in many metabolic disorders, such as diabetes, metabolic-associated liver diseases and obesity. Skeletal muscle, in addition to its role as a reservoir and consumer of energy and carbohydrate metabolism, is involved in this inter-organs’ communication through different secreted products: myokines, exosomes and enzymes, for example. Interestingly, resistance exercise has been shown to have a beneficial impact on different metabolic pathways, such as lipid oxidation in different organs through their secreted products. In this review, we will mainly focus on myokines and their effects on non-alcoholic fatty liver disease, and their complication: non-alcoholic steatohepatitis and HCC.
PMID:37049569 | DOI:10.3390/nu15071729
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Myokines: Crosstalk and Consequences on Liver Physiopathology
🌐 90 Days
VR Related Evidence Matrix
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- Spatial genomics: mapping human steatotic liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Bacteroides and NAFLD: pathophysiology and therapy
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Emerging roles of RNA-binding proteins in fatty liver disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Inflammatory liver diseases and susceptibility to sepsis
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Gene-by-Environment Interaction in Non-Alcoholic Fatty Liver Disease and Depression: The Role of Hepatic Transaminases
- Compromised very-low density lipoprotein induced polyunsaturated triglyceride accumulation in N-nitrosodiethylamine-induced hepatic steatosis
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
- 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine-choline-deficient diet and Western diet mouse models
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- The double roles of T cell-mediated immune response in the progression of MASLD
- Potent Efficacy of 3-Amino-4-hydroxy Benzoic Acid, a Small Molecule Having Anti-fibrotic Activity, in a Mouse Model of Non-alcoholic Steatohepatitis
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis
- Hepatocellular Carcinoma in Ceará: Epidemiology and Treatment in a Reference Liver Transplant Center in Northeast Brazil
- COVID-19 in Individuals with Chronic Liver Diseases
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- The gut-liver axis in fatty liver disease: role played by natural products
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
Evidence Blueprint
Myokines: Crosstalk and Consequences on Liver Physiopathology
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Myokines: Crosstalk and Consequences on Liver Physiopathology
🌐 365 Days
VR Related Evidence Matrix
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Glucosinolates Extracts from Brassica juncea Ameliorate HFD-Induced Non-Alcoholic Steatohepatitis
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Loss of cis-PTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Towards precision medicine in non-alcoholic fatty liver disease
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Corrected and republished from: Metabolic associated liver disease
- Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metabolism
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Molecular insights on intracellular Wnt/β-catenin signaling in alcoholic liver disease
- Molecular insights on intracellular Wnt/β-catenin signaling in alcoholic liver disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Cellular and molecular effects of fipronil in lipid metabolism of HepG2 and its possible connection to non-alcoholic fatty liver disease
- Miniseries: Established pharmacological targets for NASHFXR agonists in NASH treatment
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma
- High-cholesterol diet in combination with hydroxypropyl-beta-cyclodextrin induces NASH-like disorders in the liver of rats
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- 6-Shogaol Ameliorates Liver Inflammation and Fibrosis in Mice on a Methionine- and Choline-Deficient Diet by Inhibiting Oxidative Stress, Cell Death, and Endoplasmic Reticulum Stress
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
- Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
- Spatial genomics: mapping human steatotic liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease
- Hormone action and liver disease, a complex interplay
- Modelling porcine NAFLD by deletion of leptin and defining the role of AMPK in hepatic fibrosis
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma